Research Use Only Notice: This article is intended for qualified laboratory and scientific personnel. It reviews molecular identity, experimental models, analytical-quality principles, and published preclinical and human evidence.
It does not provide instructions for human or veterinary use, dosing, administration, reconstitution, compounding, or personal experimentation. No statement in this article should be interpreted as evidence of clinical efficacy, comprehensive human safety, therapeutic suitability, or regulatory approval.
AOD9604 is a synthetic peptide derived from the C-terminal region of human growth hormone (hGH). It has been investigated in experimental studies of adipose-tissue lipid metabolism, substrate oxidation, body-weight change, and beta-adrenergic-associated metabolic adaptation.

The evidence base is limited and uneven. The most frequently cited mechanistic findings come from a small group of obese-rodent studies published around the beginning of the 2000s. Human obesity studies were also conducted during pharmaceutical development, but the largest reported placebo-controlled study did not demonstrate a statistically significant weight-loss benefit, and development for obesity was discontinued. The detailed results of that late-stage study were not published as a full peer-reviewed clinical paper, which limits independent appraisal.[18]
Many molecular events discussed alongside AOD9604—such as cyclic AMP accumulation, protein kinase A activation, hormone-sensitive lipase phosphorylation, perilipin remodeling, and mitochondrial fatty-acid oxidation—belong to established adipocyte biology. These events should not be presented as directly demonstrated AOD9604 mechanisms unless the relevant endpoint was measured in an AOD9604-specific experiment.
Literature Scope and Evidence Hierarchy
This article is an evidence-informed narrative review rather than a systematic review or meta-analysis. It prioritizes original AOD9604 studies, authoritative chemical databases, regulatory assessments, and established methodological reviews relevant to lipid metabolism and peptide characterization.
The literature was interpreted using four evidence categories:
- Direct AOD9604 evidence: endpoints measured in an experiment that clearly identified the tested material as AOD9604.
- Related-compound evidence: findings from hGH, the unmodified hGH 177–191 fragment, AOD9401, or later development codes associated with the same peptide identity.
- General biological framework: established adipocyte, mitochondrial, or analytical science used to interpret possible mechanisms.
- Unresolved hypotheses: mechanistic proposals that remain plausible but have not been directly demonstrated in the relevant AOD9604 metabolic model.
Because terminology, peptide form, assay design, and reporting quality vary across the historical literature, study conclusions should remain tied to the exact sequence, disulfide configuration, counterion or salt form, formulation, species, route, exposure period, and endpoint used.
Molecular Identity of AOD9604
AOD9604 is commonly described as a synthetic 16-amino-acid peptide comprising an N-terminal tyrosine linked to the human growth hormone 177–191 region. Its sequence is:
YLRIVQCRSVEGSCGF
The two cysteine residues form an intramolecular disulfide bond between Cys7 and Cys14. PubChem lists the free peptide with molecular formula C78H123N23O23S2 and an average molecular weight of approximately 1,815.1 g/mol.[1]
Observed mass-spectrometric signals can vary with charge state, adduct formation, isotope distribution, ionization conditions, and data processing. Accordingly, observed m/z, deconvoluted neutral mass, theoretical monoisotopic mass, average molecular weight, and the mass of a salt or solvated material should be reported separately.
AOD9604 free base and AOD9604 acetate should not be treated as analytically identical bulk drug substances. They share the same active peptide moiety, but their molecular formula, total material mass, counterion contribution, water content, and batch assay may differ. FDA specifically evaluated the free base and acetate as distinct bulk drug substances.[18]
AOD9604 should also be distinguished from full-length hGH, the unmodified hGH 177–191 fragment, and the related historical research peptide AOD9401.
An earlier study of an unmodified synthetic hGH 177–191 sequence reported an antilipogenic effect in rat adipose tissue but did not detect a significant lipolytic effect by glycerol release under the tested conditions.[2]
AOD9401 was investigated separately in Zucker fatty rats and isolated adipose tissue. That study reported changes in hormone-sensitive lipase activity, acetyl-CoA carboxylase activity, diacylglycerol release, adipocyte size, and body-weight gain in the specific models used.[3]
Results obtained with full-length hGH, an unmodified hGH fragment, AOD9401, or another related sequence should not be assigned to AOD9604 unless the tested material had the same peptide sequence, disulfide configuration, analytical identity, and relevant material form.
What Direct AOD9604 Studies Reported
Findings in Obese Zucker Rats
A published study evaluated AOD9604 in obese Zucker rats under a controlled laboratory protocol. The investigators reported reduced cumulative body-weight gain relative to control animals and increased lipolytic activity in isolated adipose tissue obtained from AOD9604-exposed animals.
The same study used a euglycemic-clamp method and did not observe the adverse insulin-sensitivity effect associated with intact hGH under the compared experimental conditions.[4]
These findings are limited to the rat strain, exposure protocol, controls, endpoints, and analytical methods described in that study. They do not establish a universal response across species, cell systems, experimental concentrations, or material preparations.
Findings in Obese ob/ob Mice
A separate study examined AOD9604 in obese ob/ob mice and lean C57BL/6J mice. The investigators assessed body-weight change, food intake, resting energy expenditure, fat oxidation, glucose oxidation, plasma glucose, insulin, and plasma glycerol.
Under the reported conditions, AOD9604 reduced body-weight gain in obese mice and was associated with increased whole-body fat oxidation and increased plasma glycerol, which was interpreted as an index of lipolysis.[5]
The study also tested AOD9604 in BaF-B03 cells engineered to express the human growth hormone receptor. In that assay, AOD9604 did not compete with radiolabeled hGH for receptor binding and did not stimulate the receptor-dependent cellular proliferation observed with full-length hGH.[5]
This supports a distinction between AOD9604 and full-length hGH in the specific receptor-binding and proliferation assays used. It does not identify the direct molecular target responsible for the reported adipocyte or whole-body metabolic effects.
Findings in Beta-3-Adrenergic-Receptor Knockout Mice
Another mouse study investigated the relationship between AOD9604 and beta-3-adrenergic-receptor biology.
In obese wild-type mice, chronic experimental exposure was associated with reduced body weight and body fat, increased lipolytic sensitivity, and increased beta-3-adrenergic-receptor RNA expression in adipose tissue.
In beta-3-adrenergic-receptor knockout mice, the chronic body-weight and lipolysis changes observed in wild-type controls were not reproduced. Acute AOD9604 exposure, however, still increased energy expenditure and fat oxidation in the knockout animals.[6]
The investigators concluded that the lipolytic actions were not explained by direct beta-3-receptor activation, although increased receptor expression could contribute to enhanced lipolytic sensitivity after longer exposure.[6]
The most defensible description is that AOD9604 was associated with beta-3-adrenergic-receptor-related adaptations in mouse adipose tissue, while the direct molecular target responsible for the reported metabolic effects remained unresolved.
LAT8881 and LanCL1: Relevant but Not Metabolic Proof
The U.S. National Center for Advancing Translational Sciences GSRS record lists LAT-8881 and AOD-9604 as names associated with the same peptide substance identity.[7]
In a 2026 neuropathic-pain study, photoaffinity-probe experiments identified LanCL1 as a binding target of LAT8881-derived probe material in nervous-system models, and LanCL1 knockdown blocked the reported LAT8881 activity in those models.[8]
Those data are important for target biology in neuropathic-pain systems, but they do not establish LanCL1 as the mediator of adipocyte lipolysis, fat oxidation, or body-weight effects. Target engagement remains context dependent, and metabolic mediation would require direct testing in adipocytes, adipose tissue, and whole-body metabolic models.
Human Obesity Evidence
Human development data should be separated from the preclinical mechanistic literature. FDA’s 2024 review summarized several early human studies and the later OPTIONS study.
The OPTIONS study was described as a double-blind, placebo-controlled trial in 502 adults with obesity who received oral AOD9604 or placebo once daily for 24 weeks together with a diet-and-exercise program. The primary efficacy assessment included weight loss at 12 weeks. The reported results did not show a statistically significant difference in weight loss between AOD9604 and placebo.[18]
FDA’s review also noted that pharmaceutical development for obesity was subsequently terminated and that detailed study design and results were not available in the peer-reviewed medical literature. This prevents a full independent assessment of randomization, attrition, subgroup analyses, multiplicity, exposure-response behavior, and complete adverse-event reporting.[18]
Therefore, the available human evidence does not establish clinically meaningful efficacy for obesity. Nor does short-term oral exposure evidence establish the safety of other routes, formulations, long-term repeated exposure, or independently manufactured materials.
The Canonical Adipocyte Lipolysis Framework
Lipolysis is the regulated hydrolysis of triglycerides stored in intracellular lipid droplets. It is not controlled by a single enzyme.
In the commonly accepted sequential model:
- Adipose triglyceride lipase (ATGL) initiates hydrolysis of triglyceride to diacylglycerol.
- Hormone-sensitive lipase (HSL) has strong activity toward diacylglycerol and contributes substantially to stimulated lipolysis.
- Monoacylglycerol lipase (MGL) completes hydrolysis of monoacylglycerol to glycerol and a fatty acid.
ATGL, HSL, MGL, lipid-droplet proteins, coactivators, inhibitory proteins, intracellular localization, and substrate accessibility all influence the measured rate of lipid mobilization.[9]
The cAMP–PKA Regulatory System
In canonical beta-adrenergic stimulation, activation of a Gs-coupled receptor increases adenylyl-cyclase activity and raises intracellular cyclic AMP. Cyclic AMP activates protein kinase A, which regulates components of the lipid-droplet lipolysis system.
PKA-dependent phosphorylation of HSL contributes to its activation and translocation from the cytoplasm to the lipid-droplet surface. PKA also phosphorylates perilipin 1, reorganizing regulatory proteins around the droplet and increasing lipase access to stored lipid.
HSL residue numbering differs across species and protein isoforms. Site numbers reported in one species should not be transferred to another without confirming sequence correspondence.[10]
The cAMP–PKA–HSL–perilipin sequence is an established framework for stimulated adipocyte lipolysis. It is not, by itself, proof that AOD9604 directly activates adenylyl cyclase, raises cAMP, activates PKA, phosphorylates a specific HSL residue, or phosphorylates perilipin.
Demonstrating a complete AOD9604-dependent pathway would require matched measurements such as:
- intracellular cAMP concentration;
- PKA activity or validated substrate phosphorylation;
- species-appropriate HSL phosphorylation;
- perilipin phosphorylation;
- HSL, ATGL, and ABHD5/CGI-58 localization or interaction;
- glycerol and non-esterified fatty-acid release;
- receptor-specific inhibition and genetic loss-of-function controls;
- direct target-binding or target-engagement evidence;
- material-identity, stability, and concentration verification in the assay medium.
Interpreting Glycerol and Fatty-Acid Release
Glycerol release is widely used as a marker of adipocyte triglyceride hydrolysis. White adipocytes generally have relatively low glycerol-kinase activity, which limits glycerol reutilization and makes extracellular glycerol a useful lipolysis readout.
However, glycerol release should be measured within a validated linear interval and interpreted with assay duration, tissue mass or cell number, medium composition, albumin concentration, viability, baseline release, and fatty-acid measurements.
Both glycerol and fatty-acid release can be quantified in adipocytes or ex vivo adipose tissue, but measured values are affected by reuptake, re-esterification, substrate binding, sampling time, and nonlinear accumulation.[11]
Increased extracellular glycerol supports increased triglyceride hydrolysis under the tested conditions, but it does not independently establish:
- the upstream receptor or molecular target;
- direct beta-3-receptor binding;
- a complete cAMP–PKA mechanism;
- increased mitochondrial fatty-acid oxidation;
- long-term reduction in adipose-tissue mass;
- translation to another tissue, species, or route of exposure.
Non-esterified fatty acids released during lipolysis may bind extracellular albumin, be taken up by surrounding cells, undergo oxidation, or be re-esterified into triglycerides. A mismatch between glycerol and fatty-acid release may therefore reflect fatty-acid handling rather than an analytical error.
Beta-3-Adrenergic Pathway Association
The beta-3-adrenergic receptor is an important regulator of adipose-tissue metabolism in rodents. Activation of rodent adipocyte beta-3 receptors can promote cAMP signaling, stimulated lipolysis, and thermogenic responses.
The AOD9604 knockout-mouse study supports an association between chronic AOD9604 responses and beta-3-receptor expression or availability, but it does not establish AOD9604 as a classical direct beta-3-receptor agonist.
The persistence of acute energy-expenditure and fat-oxidation responses in beta-3-receptor knockout mice indicates that at least some short-term effects occurred without functional beta-3 receptors in that model.[6]
Species Differences
Beta-3-adrenergic-receptor expression and regulation are not identical in rodents and humans. Comparative molecular analyses have identified species- and tissue-specific differences in beta-3-receptor transcription and expression, limiting direct extrapolation from rodent adipose tissue to human adipose biology.[12]
Observations in ob/ob mice, Zucker rats, knockout mice, or mouse-derived adipocyte systems should therefore remain explicitly labeled as rodent or preclinical findings.
Pharmacological similarity to a known beta-3 agonist, inhibition by a nonselective antagonist, or convergence on a downstream signal would not independently prove direct receptor binding. Strong target identification normally requires orthogonal evidence such as direct binding, receptor-specific functional assays, selective antagonism, genetic loss of function, rescue experiments, and biophysical or chemical target-engagement analysis.
From Lipid Mobilization to Fatty-Acid Oxidation
Lipolysis and fatty-acid oxidation are related but distinct processes.
Lipolysis releases fatty acids from stored triglycerides. Oxidation requires fatty-acid transport and activation, delivery to the appropriate organelle, beta-oxidation, and coupling to downstream energy metabolism.
Fatty-Acid Uptake and Handling
Extracellular fatty acids can enter cells through a combination of diffusion and protein-facilitated transport. In metabolically active tissues, fatty-acid handling may involve CD36, plasma-membrane fatty-acid-binding protein, and fatty-acid transport proteins, although their relative contribution depends on tissue and physiological state.[13]
The cited core AOD9604 studies did not establish that AOD9604 directly regulates CD36, FABPpm, or FATP expression or trafficking. These proteins are potential downstream research endpoints, not confirmed AOD9604 targets.
Mitochondrial Beta-Oxidation
Before long-chain fatty acids undergo mitochondrial beta-oxidation, they are activated to fatty acyl-CoA. Carnitine palmitoyltransferase 1 forms acylcarnitine at the outer mitochondrial membrane; carnitine-acylcarnitine translocase transfers it across the inner membrane; and carnitine palmitoyltransferase 2 regenerates fatty acyl-CoA in the matrix. The beta-oxidation spiral then generates acetyl-CoA and reduced cofactors that support the citric-acid cycle and oxidative phosphorylation.
CPT1 activity is influenced by metabolic conditions, including inhibition by malonyl-CoA. Increased fatty-acid availability alone does not guarantee increased mitochondrial oxidation.[14]
The obese-mouse study reported increased whole-body fat oxidation under defined AOD9604 experimental conditions.[5]
That finding should not be expanded into a universal claim that AOD9604 directly activates CPT1, increases mitochondrial number, induces oxidative gene expression, or increases fatty-acid oxidation in every tissue or model.
Indirect Calorimetry and Respiratory Exchange Ratio
Indirect calorimetry estimates energy expenditure and substrate use from oxygen consumption and carbon-dioxide production.
The respiratory exchange ratio is calculated as carbon-dioxide production divided by oxygen consumption. Under appropriate steady-state conditions, values closer to 0.7 are associated with a greater relative contribution from fat oxidation, whereas values closer to 1.0 are associated with a greater relative contribution from carbohydrate oxidation.
RER is affected by feeding status, activity, stress, circadian phase, non-steady-state conditions, acid-base balance, and experimental methodology. It should be interpreted together with oxygen consumption, carbon-dioxide production, energy expenditure, food intake, locomotor activity, and body composition.[15]
A lower RER indicates a shift in the relative mixture of oxidized substrates under the measurement conditions. It does not independently prove greater total energy expenditure or long-term adipose loss.
Thermogenesis and UCP1: An Unresolved Research Area
Uncoupling protein 1 is a mitochondrial inner-membrane protein with an established role in brown-adipose-tissue thermogenesis. When functionally activated, UCP1 permits proton conductance that reduces coupling between substrate oxidation and ATP production.
UCP1 transcript abundance does not necessarily predict protein abundance, and protein abundance alone does not prove increased thermogenic flux.
Functional assessment may require mitochondrial respiration, proton-leak measurements, tissue temperature, oxygen consumption, adrenergic responsiveness, cold challenge, or whole-body energy-expenditure measurements.[16]
The principal AOD9604 studies cited here did not establish a complete AOD9604-to-UCP1 pathway or demonstrate direct induction of UCP1 transcription, UCP1 activity, white-adipose browning, or functional thermogenesis.
UCP1, mitochondrial respiration, brown-adipose histology, and tissue temperature may be appropriate endpoints for future experiments, but they should be described as proposed measurements rather than established AOD9604 effects.
Gene-Expression Claims Require Direct Evidence
Acute signaling and gene-expression adaptation occur on different time scales.
Phosphorylation, enzyme translocation, glycerol release, and fatty-acid release can change over minutes or hours. Messenger-RNA changes generally require longer observation periods, while tissue remodeling and altered depot mass may require still longer experiments.
Potential endpoints in lipid-metabolism research include:
- HSL and ATGL abundance, phosphorylation, localization, and activity;
- perilipin 1 and ABHD5/CGI-58 regulation;
- CPT1 isoforms and mitochondrial fatty-acid transport;
- MCAD and other beta-oxidation enzymes;
- PGC-1alpha and mitochondrial-biogenesis markers;
- UCP1 and other thermogenic markers;
- leptin and adiponectin expression;
- beta-adrenergic-receptor expression.
Among these categories, increased beta-3-adrenergic-receptor RNA expression was directly reported in the cited AOD9604 mouse study.[6]
The core AOD9604 studies do not provide a validated comprehensive gene-expression signature covering HSL, ATGL, CPT1, MCAD, PGC-1alpha, UCP1, leptin, and adiponectin.
These genes should not be described as established AOD9604-regulated targets without study-specific information on model, tissue, exposure, assay platform, normalization, effect size, multiple-testing control, and statistical analysis.
Tissue-Level Interpretation
Changes in body weight or adipose mass can result from altered food intake, hydration, lean mass, lipid synthesis, lipid mobilization, substrate oxidation, activity, thermogenesis, gastrointestinal effects, or tissue-specific adaptation.
A tissue-level metabolic study should ideally report:
- longitudinal body-weight curves rather than only a final value;
- food intake and, where justified, pair-fed controls;
- fat mass and lean mass;
- individual adipose-depot weights;
- organ weights;
- adipocyte-size distributions;
- plasma glycerol and fatty-acid concentrations;
- glucose, insulin, and insulin-sensitivity measurements;
- energy expenditure and locomotor activity;
- liver and muscle lipid accumulation;
- histology and molecular endpoints;
- peptide exposure, integrity, and assay-medium stability.
Adipose depots differ in vascularization, innervation, adipocyte size, receptor expression, inflammatory state, and metabolic function. Studies should identify the exact depot rather than referring generally to “fat tissue.”
The currently cited evidence does not establish a universal conclusion that one specific visceral depot responds more strongly than all subcutaneous depots.
Evidence-Strength Summary
| Evidence category | Current interpretation |
|---|---|
| More directly supported preclinical observations | Reduced body-weight gain in specific obese Zucker-rat and ob/ob-mouse protocols; increased adipose-tissue lipolytic activity in the Zucker-rat study; increased plasma glycerol and whole-body fat oxidation in obese mice; lack of hGH-receptor competition and receptor-dependent proliferation in the tested engineered cell system; increased beta-3-receptor RNA after chronic exposure; and loss of selected chronic responses with persistence of some acute responses in beta-3-receptor knockout mice.[4][5][6] |
| Human efficacy | Not established. The 502-participant OPTIONS study did not show a statistically significant weight-loss difference from placebo, and development for obesity was discontinued.[18] |
| Biologically plausible but not fully demonstrated | Direct convergence on cAMP–PKA signaling; site-specific HSL phosphorylation; perilipin phosphorylation; direct modulation of ATGL or ABHD5/CGI-58; direct regulation of fatty-acid transport proteins; direct activation of mitochondrial beta-oxidation enzymes; and direct induction of thermogenic gene programs. |
| Unresolved molecular target | LanCL1 has been identified as a LAT8881 binding and functional target in neuropathic-pain models, but it has not been established as the mediator of adipocyte or whole-body metabolic effects.[8] |
| Conclusions not supported by the reviewed evidence | Clinical effectiveness; comprehensive human safety; suitability for personal or veterinary use; a dosing or administration protocol; equivalence between rodent and human adipose responses; proof that HPLC purity establishes biological safety; or proof that increased glycerol release necessarily produces long-term fat loss. |
Common Misinterpretations
- Glycerol release is not identical to long-term adipose reduction. It supports triglyceride hydrolysis during the measurement period but does not establish the final fate of released fatty acids or net long-term energy balance.
- Increased fatty-acid availability is not identical to increased oxidation. Fatty acids may be oxidized, re-esterified, redistributed, or stored in another tissue.
- Beta-3-pathway association is not proof of direct beta-3-receptor agonism. The knockout findings indicate a more complex relationship involving chronic receptor-associated adaptation and beta-3-independent acute effects.
- A canonical pathway diagram is not compound-specific evidence. The cAMP–PKA–HSL pathway can guide experimental design, but each step must be measured before it is assigned to AOD9604.
- Messenger-RNA changes are not equivalent to protein function or metabolic flux. Transcript data should be supported by protein, phosphorylation, localization, enzyme-activity, or flux measurements.
- UCP1 expression is not sufficient proof of thermogenesis. Functional mitochondrial, tissue, and whole-animal measurements are required.
- Rodent findings should not be presented as human outcomes. Species differences in receptor biology, metabolic rate, thermogenic capacity, pharmacokinetics, and peptide handling materially affect interpretation.
- A shared sequence name does not eliminate material-quality differences. Free base, acetate, hydration state, assay value, impurity profile, aggregation, and degradation can alter the composition of the tested material.
Analytical Identity and Certificate-of-Analysis Interpretation
Molecular identity data and a batch Certificate of Analysis answer different questions.
A research-peptide COA may include:
- batch or lot number;
- peptide sequence or chemical identity;
- mass-spectrometric result;
- reversed-phase HPLC purity;
- appearance;
- water content;
- counterion content;
- residual-solvent results;
- net peptide content or assay value;
- storage conditions;
- manufacturing and testing dates.
An HPLC area-percentage result estimates the relative chromatographic contribution of detected components under a specific method. It does not independently establish molecular identity, net peptide content, water content, counterion content, residual-solvent content, aggregate content, sterility, endotoxin status, or suitability for a biological application.
Mass spectrometry can support identity confirmation, but a matching mass alone does not characterize sequence-related impurities, positional isomers, disulfide variants, aggregates, residual reagents, or all degradation products.
For a disulfide-containing synthetic peptide, a stronger analytical package may require orthogonal identity and purity methods, evidence supporting disulfide configuration, impurity profiling, assay or net peptide content, water and counterion determination, residual-solvent testing, and stability-indicating methods. The required tests depend on the intended analytical purpose and cannot be inferred from a single HPLC chromatogram.
ICH Q2(R2) describes analytical-procedure performance characteristics such as specificity or selectivity, accuracy, precision, detection limit, quantitation limit, linearity, range, and robustness, as applicable to the intended use of the procedure.[17]
A COA documents selected quality-control results for a specific batch. It does not demonstrate clinical efficacy, comprehensive safety, sterility, endotoxin control, or regulatory approval unless those attributes were specifically tested under suitable validated methods and the relevant regulatory requirements were met.
Current U.S. Regulatory and Quality Context
AOD9604 is not a component of an FDA-approved drug. FDA’s 2024 evaluation of AOD9604 free base and AOD9604 acetate for possible inclusion on the section 503A bulk drug substances list concluded that the available balance of physicochemical characterization, effectiveness, and safety information weighed against inclusion.[18]
FDA identified limitations in characterization data, potential immunogenicity concerns for injectable use, limited information for proposed routes, lack of established effectiveness for obesity, and insufficient long-term safety information. FDA also noted that submitted COA information did not include results addressing all relevant impurity, aggregate, bioburden, and bacterial-endotoxin attributes.[18]
On its current compounding-risk page, FDA states that compounded drugs containing AOD9604 may present immunogenicity risk for certain routes and may involve complexities in peptide-related impurities and active-pharmaceutical-ingredient characterization. FDA also states that available safety information is absent or limited and that serious adverse events have been identified as potentially associated, while causality remains unclear.[19]
These regulatory statements should not be misread as proof that every material labeled AOD9604 has the same risk profile. They indicate that identity, manufacture, impurity control, aggregation, formulation, route, and exposure cannot be assumed safe from the peptide name or an HPLC purity value alone.
Regulatory status is jurisdiction specific and may change. This article therefore makes the limited statement that AOD9604 is not an FDA-approved therapeutic drug in the United States and does not claim to have exhaustively verified every human or veterinary regulatory database worldwide.
Research Interpretation Checklist
Before drawing conclusions from an AOD9604 experiment, confirm:
- the exact peptide sequence and Cys7–Cys14 disulfide configuration;
- whether the material is AOD9604 free base, acetate, another salt, hGH 177–191, AOD9401, or another related fragment;
- counterion, water content, net peptide content, and concentration basis;
- batch-specific purity and impurity profile;
- mass-spectrometric identity and, where relevant, disulfide confirmation;
- sample stability in storage, formulation, and assay medium;
- species, strain, sex, age, and metabolic condition;
- the exact cell type or adipose depot;
- exposure duration, sampling schedule, and concentration verification;
- vehicle and appropriate positive and negative controls;
- whether cytotoxicity, membrane damage, or loss of viability was excluded;
- whether glycerol and fatty-acid release were measured within a validated linear interval;
- whether molecular endpoints were directly measured or inferred from general biology;
- whether statistical methods, normalization, and multiple comparisons were appropriate;
- whether conclusions remain limited to the tested experimental system.
Conclusion
The most defensible interpretation of the published literature is that AOD9604 produced measurable lipid-metabolism-related effects in several defined obese-rodent models and showed a complex association with beta-3-adrenergic-receptor biology.
The evidence does not establish a complete receptor-to-effector pathway for the reported adipocyte effects. Direct activation of cAMP–PKA signaling, site-specific HSL phosphorylation, perilipin remodeling, ATGL regulation, mitochondrial enzyme activation, UCP1-dependent thermogenesis, and a comprehensive gene-expression program remain unproven unless directly measured in an AOD9604-specific experiment.
Human obesity development did not establish statistically significant weight-loss efficacy in the largest reported placebo-controlled trial, and the available clinical record is insufficient to establish comprehensive safety, particularly across material forms, formulations, routes, and long-term exposure.[18]
LanCL1 has been identified as a binding and functional mediator of LAT8881 activity in neuropathic-pain models, but its role in adipocyte or whole-body metabolic effects remains unresolved.[8]
Finally, peptide name, sequence, HPLC area purity, and matching nominal mass are not interchangeable with a complete material-quality assessment. Reliable interpretation requires verified identity, relevant impurity and aggregate control, net content, stability, and experimental traceability.
References
- PubChem. AOD9604, CID 71300630.
- Wu Z, Ng FM. Antilipogenic action of synthetic C-terminal sequence 177–191 of human growth hormone.
- Ng FM et al. Molecular and cellular actions of a structural domain of human growth hormone (AOD9401) on lipid metabolism in Zucker fatty rats.
- Ng FM et al. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.
- Heffernan MA et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.
- Heffernan M et al. The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta-3-AR knockout mice.
- NCATS Global Substance Registration System. LAT-8881 / AOD-9604 substance record.
- Spanswick D et al. Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain. PAIN. 2026.
- Duncan RE et al. Regulation of lipolysis in adipocytes.
- Sztalryd C, Brasaemle DL. The perilipin family of lipid-droplet proteins: gatekeepers of intracellular lipolysis.
- Bridge-Comer PE, Reilly SM. Measuring the rate of lipolysis in ex vivo murine adipose tissue and primary preadipocytes differentiated in vitro.
- Granneman JG et al. Analysis of human and rodent beta-3-adrenergic-receptor messenger ribonucleic acids.
- van Hall G. The physiological regulation of skeletal-muscle fatty-acid supply and oxidation.
- Houten SM, Wanders RJA. A general introduction to the biochemistry of mitochondrial fatty-acid beta-oxidation.
- Das Gupta R et al. Indirect calorimetry: from bench to bedside.
- Harms M, Seale P. A new era in brown-adipose-tissue biology: molecular control of brown-fat development and energy homeostasis.
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures.
- U.S. Food and Drug Administration. Evaluation of AOD9604-related bulk drug substances for inclusion on the section 503A bulk drug substances list. Pharmacy Compounding Advisory Committee briefing document, December 4, 2024.
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks.
Research Use Only Disclaimer
Research Use Only: The materials and studies discussed in this article are presented solely for scientific and informational review. This article does not constitute medical, clinical, veterinary, pharmaceutical-compounding, or treatment advice. It does not provide a basis for administration to humans or animals.